As an asset-based health sciences and regenerative medicine company, Cardium Therapeutics focuses on acquiring and developing innovative products and businesses that have the potential to fulfill significant unmet medical needs.
In its quest to develop a portfolio of medical product candidates for eventual commercialization, Cardium's strategy is to build on its core products and candidates and focus on five specific elements:
•Advance its ASPIRE Generx® clinical study for patients with advanced coronary artery disease at major medical centers in Russia
•Establish development and commercialization partnerships for Generx® in newly industrializing countries such as India, China, and Brazil
•Secure commercialization partners for its FDA-cleared Excellagen® advanced wound care product
•Expand the To Go Brands® healthy nutraceutical supplement brand platform
•Seek out high-potential acquisition and license opportunities
With its existing lineup of brands and products, the company has established a firm presence in the cardiovascular, wound care management, and nutraceutical markets. The design of the Cardium's business model creates multiple opportunities for growth while mitigating risk by eliminating the company's reliance on any single technology platform or product type.
Currently, the company's lead commercial product is Excellagen, which received U.S. FDA clearance for marketing and sale in the United States. Cardium plans to advance the product's market reach in the U.S. and internationally, as well as seeks to develop new extensions and applications of the products. The company is working to obtain marketing and sale approval of the product in South Korea as well as through the CE Mark application process in the European Union.
For more information, visit cardiumthx.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com